Medical Doctor Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Raed Odeh

Psychiatry Elizabeth, NJ Medical Doctor

NPI 1386263127 CMS profile 11695859

654 E Jersey St, Elizabeth, NJ 07206

Open in the dashboard

General payments

$19,007

238 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Raed Odeh of Elizabeth, NJ is reported in the CMS Open Payments database as having received $19,007 across 238 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17,644 206
2024 General $1,363 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Raed Odeh
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Raed Odeh were reported at $17,644. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Raed Odeh Psychiatry median Middle half National median
2019 $0 $184 $59–$605 $163
2020 $0 $119 $36–$372 $114
2021 $0 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $1,363 $179 $57–$673 $164
2025 $17,644 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. E.R. Squibb & Sons, L.L.C. $13,414 51 payments
  2. ITI, Inc. $1,167 21 payments
  3. Alkermes, Inc. $1,098 34 payments
  4. Teva Pharmaceuticals USA, Inc. $917 31 payments
  5. Janssen Pharmaceuticals, Inc $447 14 payments
  6. Otsuka America Pharmaceutical, Inc. $413 17 payments
  7. Vanda Pharmaceuticals Inc. $325 7 payments
  8. AbbVie, Inc. $282 19 payments
  9. Neurocrine Biosciences, Inc. $264 16 payments
  10. Axsome Therapeutics, Inc. $264 3 payments
  11. Other $417 25 payments

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Consulting Fee $7,015 1 payment
  2. Food and Beverage $6,898 231 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,680 2 payments
  4. Travel and Lodging $1,304 3 payments
  5. Education $109 1 payment
Products named General payments · program years 2024–2025
  1. COBENFY $6,383 49 payments
  2. LYBALVI Cns $937 29 payments
  3. CAPLYTA $683 16 payments
  4. LYBALVI Cns $575 7 payments
  5. LYBALVI Cns $575 7 payments
  6. LYBALVI Cns $575 7 payments
  7. ARISTADA Cns $523 27 payments
  8. ARISTADA Cns $523 27 payments
  9. ARISTADA Cns $523 27 payments
  10. ARISTADA Cns $523 27 payments
  11. Other $4,206 152 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

22

Median for Psychiatry & Neurology: 100

Drug cost

$263

Median for Psychiatry & Neurology: $2,986

Branded share of claims

0%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Quetiapine Fumarate Generic 11 $163
Clonazepam Generic 11 $100

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $484
$484 — —
LYBALVI
  • Alkermes, Inc. $184
$184 — —
Auvelity
  • Axsome Therapeutics, Inc. $125
$125 — —
FANAPT
  • Vanda Pharmaceuticals Inc. $123
$123 — —
PERSERIS
  • Indivior Inc. $112
$112 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

238 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record